Ulcerative Colitis

About Ulcerative Colitis & Proctitis When you first learn that you have ulcerative colitis, you will probably feel overwhelmed. You may not even have heard of ulcerative colitis until now. And even if you are familiar with the disorder, the information you have may be pretty limited. That's all about to change. Clearly, you will have many questions about how this disease will affect you -- both now and down the road. For example, you'll want to know:

• Will I be able to work, travel, and exercise?
• Should I be on a special diet?
• How will other people react to my illness?
• Could my medications have side effects?
• How will ulcerative colitis change my life?

Learning all you can is an important step toward taking charge of your illness -- and your life. The following is an overview of ulcerative colitis. It is designed to help you understand more about the diagnosis and treatment of this illness, and its impact on the day-to-day lives of patients and their families. The better informed you are about ulcerative colitis, the more equipped you'll be to participate as an active member of your healthcare team.

What is Ulcerative Colitis?

Ulcerative colitis is a chronic (ongoing) disease of the colon, or large intestine. The disease is marked by inflammation and ulceration of the colon mucosa, or innermost lining. Tiny open sores, or ulcers, form on the surface of the lining, where they bleed and produce pus and mucus. Because the inflammation makes the colon empty frequently, symptoms typically include diarrhea (sometimes bloody) and often crampy abdominal pain.

The inflammation usually begins in the rectum and lower colon, but it may also involve the entire colon. When ulcerative colitis affects only the lowest part of the colon -- the rectum -- it is called ulcerative proctitis. If the disease affects only the left side of the colon, it is called limited or distal colitis. If it involves the entire colon, it is termed pancolitis.

Ulcerative colitis differs from another inflammatory bowel disease (IBD), Crohn's disease. Crohn's can affect any area of the gastrointestinal (GI) tract, including the small intestine and colon. Ulcerative colitis, on the other hand, affects only the colon. The inflammation involves the entire rectum and extends up the colon in a continuous manner. There are no areas of normal intestine between the areas of diseased intestine. In contrast, such so-called "skip" areas may occur in Crohn's disease. Ulcerative colitis affects only the innermost lining of the colon, whereas Crohn's disease can affect the entire thickness of the bowel wall.

Both illnesses do have one strong feature in common. They are marked by an abnormal response by the body's immune system. The immune system is composed of various cells and proteins. Normally, these protect the body from infection. In people with IBD, however, the immune system reacts inappropriately. Mistaking food, bacteria, and other materials in the intestine for foreign or invading substances, it launches an attack. In the process, the body sends white blood cells into the lining of the intestines, where they produce chronic inflammation. These cells then generate harmful products that ultimately lead to ulcerations and bowel injury. When this happens, the patient experiences the symptoms of IBD.

Neither ulcerative colitis nor Crohn's disease should be confused with irritable bowel syndrome (IBS), a disorder that affects the motility (muscle contractions) of the colon. Sometimes called "spastic colon" or "nervous colitis," IBS is not characterized by intestinal inflammation. It is, therefore, a much less serious disease than ulcerative colitis. IBS bears no direct relationship to either ulcerative colitis or Crohn's disease.

What Causes Ulcerative Colitis?

Although considerable progress has been made in IBD research, investigators do not yet know what causes this disease. Studies indicate that the inflammation in IBD involves a complex interaction of factors: the genes the persont has inherited, the immune system, and something in the environment. Foreign substances (antigens) in the environment may be the direct cause of the inflammation, or they may stimulate the body's defenses to produce an inflammation that continues without control. Researchers believe that once the IBD patient's immune system is "turned on," it does not know how to properly "turn off" at the right time. As a result, inflammation damages the intestine and causes the symptoms of IBD. That is why the main goal of medical therapy is to help patients regulate their immune system better.

CCFA-sponsored research has led to progress in the fields of immunology, the study of the body's immune defense system; microbiology, the study of microscopic organisms with the power to cause disease; and genetics. Many scientists now believe that the interaction of an outside agent (such as a virus or bacterium) with the body's immune system may trigger the disease, or that such an agent may cause damage to the intestinal wall, initiating or accelerating the disease process. Through CCFA's continuing research efforts, much more will be learned and a cure will eventually be found.

Is Ulcerative Colitis Inherited? We know that ulcerative colitis can tend to run in families. Studies have shown that up to 20 percent of people with ulcerative colitis will have a close relative with either ulcerative colitis or Crohn's disease. Most often, the affected relative of the colitis patient will also have ulcerative colitis. However, based on current research, there does not appear to be a clear-cut pattern to this inheritance. Researchers continue to seek specific genes involved in the cause of the diseases. At this time, however, there is no way to predict which, if any, family members will develop ulcerative colitis or Crohn's disease.

 

News about Ulcerative Colitis

Channel: GastroIntestinal / Gastroenterology News From Medical News Today

• Undiagnosed Celiac Disease More Common Today Than 50 Years Ago Say US Researchers

US researchers said that undiagnosed cases of celiac disease, where the immune system has a strong adverse reaction to the protein found in wheat and other grains, appear to have increased dramatically in the last 50 years. They also found, over a 45 year follow up, that people with undiagnosed celiac disease have a nearly four-fold increased risk of premature death from any cause.
• Undiagnosed Celiac Disease Associated With Nearly Quadrupled Mortality

Celiac disease, an immune system reaction to gluten in the diet, is over four times more common today than it was 50 years ago, according to findings of a Mayo Clinic study published this month in the journal Gastroenterology. The study also found that subjects who did not know they had celiac disease were nearly four times more likely than celiac-free subjects to have died during the 45 years of follow-up.
• Sucampo Reports Top-Line Results Of Phase 2 Clinical Trial Of Cobiprostone For Prevention Of NSAID-Induced Gastrointestinal Injuries

Sucampo Pharma Americas, Inc., a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), today reported top-line results from its phase 2 clinical trial of orally administered cobiprostone for the prevention of gastric ulcers and other gastrointestinal injuries in patients treated with non-steroidal anti-inflammatory drugs (NSAIDs). A total of 124 patients with osteoarthritis and/or rheumatoid arthritis at 12 sites in the U.S.
• Salmonella And E. Coli Bacteria Found In Packets Of Shelled Nuts

A recent study carried out by the Health Protection Agency and LACORS (Local Authorities Co-ordinators of Regulatory Services) has revealed the presence of Salmonella and E. coli bacteria in a small number of samples of ready-to-eat shelled nuts. Consumption of nuts has gone up, reflecting a growing preference for snacks that are both healthy and convenient.
• Celiac Disease Four Times More Common Than In 1950s

Celiac disease, an immune system reaction to gluten in the diet, is over four times more common today than it was 50 years ago, according to findings of a Mayo Clinic study published this month in the journal Gastroenterology.
• Is Midline Or Transverse Incision Better For Abdominal Surgery?

An unusual study at the Department of Surgery at Heidelberg University Hospital examined for the first time whether the incision technique used in major abdominal surgery had an effect on the results. Neither physician nor patient knew what kind of incision had been made. The study of 200 patients showed that pain perception and the healing process were unrelated to the technique used to open the abdominal cavity.
• Peptic Ulcer Bacterium Alters The Body's Defence System

Helicobacter pylori survives in the body by manipulating important immune system cells. This is shown in a thesis from the Sahlgrenska Academy. The discovery may lead to new treatments against the common peptic ulcer bacterium. About half of the world's population carries Helicobacter pylori, mainly in the stomach. Most infected individuals never experience any symptoms, but around 10% get peptic ulcers and around 1% develop stomach cancer.
• Gastrointestinal Endoscopy June Issue Study Highlights

Polyp detection rates at screening colonoscopy; EUS-based criteria for the diagnosis of chronic pancreatitis In the June issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy (ASGE), a
• Study Could Help Target New Pancreatitis Treatments

Pancreatitis is often a fatal condition, in which the pancreas digests itself and surrounding tissue. Scientists have previously found that alcohol can trigger the condition by combining with fatty acids in the pancreas, which leads to an excessive release of stored calcium ions. Once calcium ions enter cell fluid in the pancreas it activates digestive enzymes and damages the cells.
• Intestinal Cells Surprisingly Active In Pursuit Of Nutrition And Defense

Every cell lining the small intestine bristles with thousands of tightly packed microvilli that project into the gut lumen, forming a brush border that absorbs nutrients and protects the body from intestinal bacteria.
• Babies' Intestines Protected By Magic Ingredient In Breast Milk

Scientists at Queen Mary, University of London have discovered that an ingredient in human breast milk protects and repairs the delicate intestines of newborn babies. The ingredient called pancreatic secretory trypsin inhibitor, or PSTI, is found at its highest levels in colostrum - the milk produced in the first few days after birth. The lining of a newborn's gut is particularly vulnerable to damage as it has never been exposed to food or drink.
• Does Preoperative Biliary Drainage Influence The Outcome Of Resectional Surgery For Ampullary Carcinoma?

A research article published in the World Journal of Gastroenterology addresses this question. This is believed to be the first study to investigate the effect of PBD in ampullary cancer. A team of gastroenterologists led by Dr Steven Joseph Mesenas and hepatobiliary surgeons at Singapore General Hospital divided 82 patients with ampullary cancer planned for surgical resection into those with PBD (n = 35) and those without (n = 47).
• Rat Model Of Hepatic Encephalopathy And Prehepatic Portal Hypertension

A research article published in the World Journal of Gastroenterology refers. The research team lead by Dr. Gabriela Beatriz Acosta, observed that the activity of GS was increased in the hippocampus in PH rats. There was a significant decrease in glutamate uptake in both brain areas, which was more marked in the hippocampus. The decrease in glutamate uptake might be caused by deficient transport function and persistent glutamate activity, which is not metabolized.
• Human Gastric Cancer: A Potent And Selective Anti-Tumor Agent

A research article published in the World Journal of Gastroenterology refers. The research team led by Professor Yan Li from Shengjing Hospital of China Medical University studied the growth inhibitory effects of Alisol B acetat and determined its mechanism of antitumor activity in human gastric cancer cell line SGC7901. Professor Li and his colleagues found that Alisol B acetat could inhibit the proliferation of SGC7901 cell in a time and dose dependent manner.
• DOR BioPharma Announces Publication Of OrBec(R) Clinical Pulmonary Data In Bone Marrow Transplantation

DOR BioPharma, Inc.
• E Coli Confirmed In Nestlé Toll House Cookie Dough Says FDA

The US Food and Drug Administration (FDA) said yesterday, June 29, that it had found E. coli O157:H7 in a sample of prepackaged Nestlé Toll House refrigerated cookie dough that had been collected at the Nestlé factory in Danville, Virginia four days earlier.
• Health Unit Reports Three Cases Of E. Coli O157:H7 In London

Over the last five days, the Middlesex-London Health Unit has received reports of three children with E. coli O157:H7. To receive three laboratory confirmed cases of E. coli O157:H7 in such a short timeframe is unusual. In two of these cases, the common food consumed was kofta (spiced ground beef) purchased on June 14 and 15 from the Westmount Halal Food Store located at 490 Wonderland Road South. The source of the third child's infection is currently unknown.
• Simple Measures May Prevent Transmission Of Stomach Ulcer Bacteria

The stomach ulcer bacterium Helicobacter pylori is not transmitted through drinking water as previously thought, but rather through vomit and possibly faeces. This is shown in a thesis at the Sahlgrenska Academy, University of Gothenburg, Sweden. It is therefore possible to prevent the spread of the bacterium in developing countries through some fairly simple measures. 'Taking some cheap but powerful measures may prevent the spread of the bacterium.
• What Is Colorectal Cancer? What Causes Colorectal Cancer?

Any cancer - a growth, lump, tumor - of the colon and the rectum is a type of colorectal cancer. Colorectal cancer is also known as bowel cancer. The UK National Health Service says colorectal cancer is the most common cancer globally today. However, the World Health Organization says it is the second most common cancer, after lung cancer.
• Tummy Troubles -- Gastrin Key In Bacterial-Induced Stomach Cancer

Current research suggests that levels of gastrin play a key role in the development of Helicobacter-induced stomach cancer. The related report by Takaishi et al, "Gastrin is an essential cofactor for Helicobacter-associated gastric corpus carcinogenesis in C57BL/6 mice," appears in the July 2009 issue of The American Journal of Pathology.
• NYU Langone Medical Center Awarded NIH Grants Totaling $1,560,000

Two NYU Langone Medical Center researchers have received $1,560,000 in grant support for their first year of studies focused on microbiome and psoriasis and on microbiome and esophageal cancer from the National Institutes of Health (NIH). The studies being conducted at NYU Langone Medical Center are two of several projects being conducted through the NIH Roadmap for Medical Research as part of the Human Microbiome Project (HMP) taking place at institutions across the country.
• What Is Different In Reflux Esophagitis Between African-Americans And Non-Hispanic Whites?

There is minimal data evaluating the prevalence of GERD complications in any United States general population, other than non-Hispanic whites. Presently, it is thought that such complications occur less frequently in African-Americans than in non-Hispanic whites. A research group in Jacksonville, FL investigated the prevalence of reflux esophagitis between non-Hispanic whites and African-Americans.
• Almost Half UK Hospitals Not Equipped To Deal With Critical Out Of Hours Care

The British Society of Gastroenterology (BSG) is hosting a meeting at Number 11, Downing Street today to raise awareness of how more than half of Britain's hospitals are providing patients with inadequate services. A UK-wide audit shows that 60% of acute upper gastrointestinal bleeding episodes occurred out of 'normal' working hours yet 45% of hospitals do not provide out of hours endoscopy.
• Latest Erbitux Data On Metastatic Colorectal Cancer Presented At WCGIC Underline Benefits In Patients With KRAS Wild-Type Tumors

Latest Erbitux® (cetuximab) data presented today at the World Congress on Gastrointestinal Cancer (WCGIC) reinforce the value of the targeted therapy in the treatment of metastatic colorectal cancer (mCRC) patients with KRAS wild-type (wt) tumors. Results from the CRYSTALa and CELIMb trials have provided further evidence that KRAS mutation status is the current accepted standard predictive biomarker for Erbitux efficacy in patients with mCRC.
• Gastrin Plays Significant Role In Helicobacter-Induced Stomach Cancer

A group led by Columbia University Medical Center's Timothy Wang, M.D., has studied the role of Helicobacter infection in the development of stomach cancer and found that the hormone gastrin, which stimulates secretion of gastric acid, plays a key role in the development of Helicobacter-induced stomach cancer, and may have distinct effects on carcinogenesis in different parts of the stomach.